News & Events

On Friday 27^th May BCNI held a “Blood Cancer” Symposium for researchers and healthcare professionals with an interest in translational and clinical blood cancer research. This event had an excellent line-up of international speakers.

Speakers

• Prof Donald Harvey,   Director, Phase 1 Clinical Trials, Winship Cancer Institute Emory University, Atlanta, USA  "The recent evolution of phase 1 trials in drug development"- See presentation
• Dr Jim Omel,  Patient Advocate, USA "Myeloma....still much to be done" - See presentation
• Prof Alan Burnett,  Emeritus Prof  and Head of Haematology Department of Medical Genetics, Cardiff, Wales , "Can we do trials better?"-See presentation
• Prof Henk Lokhorst, Prof of Hematology, VU Medical Centre, Amsterdam, The Netherlands, "Evolving immunotherapeutic strategies in myeloma" -See presentation
• Dr Caroline Heckman, Institute for Molecular Medicine, University of Helsinki, Finland, "From biobanks and big data to precision medicine strategies in hematology" -See presentation
• Margaret Doyle, Global Medical Affairs Director, Hematology, Janssen, "BCNI- an industry perspective"     - See presentation    

Presentations on the vision and activities of Blood Cancer Network Ireland were given by

• Prof Michael O'Dwyer, BCNI Director "Development of early phase clinical trials in Ireland" - See presentation
• Dr Eva Szegezdi, BCNI Biobank leader "Introducing Blood Cancer Biobank Ireland" - See presentation
• Dr Harry Comber, BCNI Cancer Registry "Establishing an enhanced blood cancer registry for Ireland" - See Presentation

‌

Approximately 100 people attended the symposium coming from

• Universities (TCD, UCC, NUIG, QUB, GMIT, RCSI, UCD, UL, DCU)
• Hospitals and Clinical Research Facilities (Mater, Beaumont, Cork University Hospital, University Hospital Galway, MRH Tullamore, St James, Clinical Trials Ireland)
• Funding agencies (Science Foundation Ireland, Irish Cancer Society and Enterprise Ireland)
• Industry (Amgen, Novartis, Janssen, AbbVie, BMS, SuprTec Box).

Overall it was an excellent symposium that generated a lot of excitement about the latest developments in Blood Cancer research at both national and international levels.

‌